Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation

Transplant International

Volumn 28, Issue 8, 2015, Pages 980-989

  Fortune, Brett E ^a   Martinez Camacho, Alvaro ^b   Kreidler, Sarah ^c   Gralla, Jane ^d   Everson, Gregory T ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Nutrition Obesity Research Center at the University of Colorado   (United States)

Author keywords

graft survival; hepatitis C virus; liver transplantation; outcomes; patient survival; recurrent hepatitis C; Scientific Registry of Transplant Recipients

Indexed keywords

VIRUS RNA; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD; AGED; BLOOD; CASE CONTROL STUDY; EVALUATION STUDY; FACTUAL DATABASE; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84947018738     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12568     Document Type: Article

References (31)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335.
2. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C,. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8: 924; quiz e117.
3. Everhart JE, Wei Y, Eng H, et al., Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29: 1220.
4. Berenguer M, Prieto M, Rayon JM, et al., Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852.
5. Neumann UP, Berg T, Bahra M, et al., Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
6. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1.
7. Charlton M, Ruppert K, Belle SH, et al., Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120.
8. Charlton M, Seaberg E, Wiesner R, et al., Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
9. Iacob S, Cicinnati VR, Hilgard P, et al., Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84: 56.
10. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al., Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125.
11. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
12. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ,. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748.
13. Feng S, Goodrich NP, Bragg-Gresham JL, et al., Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783.
14. Ghobrial RM, Gornbein J, Steadman R, et al., Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002; 236: 315; discussion 22-3.
15. Heinzl H, Kaider A, Zlabinger G,. Assessing interactions of binary time-dependent covariates with time in cox proportional hazards regression models using cubic spline functions. Stat Med 1996; 15: 2589.
16. Everson GT, Hoefs JC, Seeff LB, et al., Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675.
17. Fried MW, Shiffman ML, Reddy KR, et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975.
18. Manns MP, McHutchison JG, Gordon SC, et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958.
19. Carrion JA, Martinez-Bauer E, Crespo G, et al., Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719.
20. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR,. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350.
21. Everson GT, Trotter J, Forman L, et al., Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255.
22. Everson GTTN, Lok AS,. Interim analysis of a controlled trial of pretransplant peginterferon alpha 2b/ribavirin to prevent recurrent hepatitis C virus infection after liver transplantation in the adult-to-adult liver transplantation study. Hepatology 2009; 9: 905.
23. Forns X, Garcia-Retortillo M, Serrano T, et al., Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389.
24. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH,. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905.
25. Bacon BR, Gordon SC, Lawitz E, et al., Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207.
26. Hezode C, Forestier N, Dusheiko G, et al., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839.
27. McHutchison JG, Manns MP, Muir AJ, et al., Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292.
28. Poordad F, McCone J Jr, Bacon BR, et al., Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195.
29. Lai JC, Verna EC, Brown RS Jr, et al., Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54: 418.
30. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003.
31. Gillespie BW, Merion RM, Ortiz-Rios E, et al., Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant 2010; 10: 1621.